Patients who switched to V-Go experienced a drop in A1c—which reversed when patients discontinued V-Go.1
Observational trial of 31 patients with diabetes mellitus previously treated with insulin pens or syringes switched to V-Go to obtain patient feedback on the patient instructions and functionality of the V-Go. For 23 patients, physicians retrospectively collected clinical data for analysis; data were collected at baseline, 12 weeks after V-Go initiation, at the end of V-Go use, and 12 weeks after the end of V-Go use.1
V-Go’s innovative insulin delivery has demonstrated significant reductions in A1c and insulin requirements compared with multiple daily injections (MDI).7
Rates of hypoglycemia did not differ from baseline over 27 weeks of V-Go therapy.2
*This value was calculated by averaging the mean upper (117) and mean lower (102) prescribed TDD. Reduction in A1c (P<0.0001) compared to baseline. Reduction in TDD (P<0.0001) compared to baseline. Prior to V-Go initiation, patients had a mean A1c of 9.4%. Based on real-world, retrospective database analysis of an electronic medical record database. Patients were adults diagnosed with diabetes mellitus, A1c ≥7%, and previously prescribed basal-bolus insulin therapy. A total of 86 patients were evaluated.
1. Rosenfeld CR, Bohannon NJ, Bode B, et al. The V-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control. Endocr Pract. 2012;18(5):660-667. 2. Lajara R, Fetchick DA, Morris TL, Nikkel C. Use of V-Go Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System. Diabetes Ther. 2015;6(4):531-545. 7. Lajara R, Nikkel C. Poster presented at: American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress; May 13-17, 2015; Nashville, TN. Poster 273T.